The latest biotech news

microbiome seres eligo flagship cancer evelo

News and Trends 17 Nov 2015

What will Happen now the Microbiome Hype has Broken into the Immuno-Oncology Field?

The Microbiome and Immuno-Oncology fields are hugely trendy in the Biotech Industry – and now a marriage between the two has finally occurred… The Microbiome field is still very new, with the launch of the US Human Microbiome Project just happening in 2008. Nonetheless, some start-ups are moving fast up the microbiome ranks, as well […]

November 17, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 17 Nov 2015

Epigenetics Drug Discovery has a New Champion!

Last week at BIO-Europe 2015 in Munich, I had the opportunity to meet Torsten Hoffmann, CSO of Proteros who told me more about the recent incursion of his company in the Epigenetics space! Proteros is a leader of the Structural Biology field. So, what is this field exactly? Usually, when a Pharmaceutical company is looking […]

November 17, 2015 - 4 minutesmins - By Joachim Eeckhout

genfit ceo mouney liver disease NASH elafibranor interview

News and Trends 16 Nov 2015

Interview with the CEO of Genfit – The Billion Euro Liver Biotech on its phase III NASH Drug

Interview with Jean-François Mouney (Chairman and CEO of Genfit) at the ‘Liver Meeting 2015‘ congress for the American Association for the study of Liver disease (AASLD) on Friday in San Francisco (US). Genfit is the European leader in NASH research (Non-alcoholic steatohepatitis), today making the news again at AASLD in San Francisco. The company, which […]

November 16, 2015 - 5 minutesmins - By Dani Bancroft

swissmedic newron xadago zambon parkinsons

News and Trends 16 Nov 2015

Swissmedic Approves Zambon and Newron Therapy against Parkinson’s

Italian Pharma Newron and its partner Zambon (from Milan) have been granted a license by Swissmedic (the regulatory agency in Switzerland) for Xadago, a new combo ‘add-on’ therapy for Parkinson’s Disease. Zambon, is a Pharmaceutical Company with a strong commitment in central nervous system (CNS) diseases. Its partner, Newron Pharmaceuticals, is a research and development biotech from northern […]

November 16, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 16 Nov 2015

What are Money-Magnet Moderna’s future plans? French Founding CEO explains here

Before the end of the mRNA conference in Berlin, I had to interview Stephane Bancel, the French founding CEO of Moderna…one of the biggest deals in Biotech today. Moderna is the mRNA therapies companies from Cambridge/Boston (US), most famous for having raised over 900 million dollars in VC money. I met Stephane one and a […]

November 16, 2015 - 1 minutemin - By Philip Hemme

News and Trends 14 Nov 2015

What happened this week? mRNA Therapies, TCR & Algae Beer

Monday: Leading TCR Immuno-oncology Biotech shows Promising Results against Cancer Tuesday: What the FUGT? We tried the Algae Bar Beer for the TransArt Fest in Copenhagen! Wednesday: Using Algae and NanoTech to Kill Cancer: An Australian-German Collaboration Thursday (two interviews): Interview: The ‘RNA’ People’s Pioneering Strategy to get mRNA Therapies onto the Market EU’s Largest Private […]

November 14, 2015 - 1 minutemin - By Philip Hemme

News and Trends 13 Nov 2015

We were at the Berlin Office Opening of the Leading German Bioinformatics Company

Berlin is hotspot which is always attracting companies in the Biotech field (including us :p). Molecular Health is a 150-strong Bioinformatic company from Heidelberg (Germany) which has also decided to open an office in the capital, to profit from its proximity to the political system. The opening took place in the new office, which was […]

November 13, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 13 Nov 2015

Curetis Molecular Diagnostics IPO Exceeds Expectations

The Southern German Med-tech for infectious disease biotech, Curetis, has sold shares up to a value of €40M, which is 10 million above its initial target, despite a lower ranged Offer price. Curetis have developed a molecular diagnostics system for hospital acquired infections (such as MRSA and Pneumonia). Their Unyvero system is a piece of […]

November 13, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 13 Nov 2015

Biotech of the Week: Lexogen and it’s Transcriptomic Approach to Disease

This week we say ‘bye for noo’ to Edinburgh and head South East, across the English Channel and through both Netherlands and Germany where we arrive at this week’s destination, Vienna, Austria. This country is the place of birth of Mozart, has the only cuisine named after a city (Viennese) and absolutely stunning scenery, it is […]

November 13, 2015 - 2 minutesmins - By Philip Hemme

seasonal influenza universal vaccine sanofi peptcell seek niaid nihr

News and Trends 12 Nov 2015

Sanofi’s COBRA Research to Tackle the Challenge of A Universal Influenza Vaccine for Winter

Sanofi Pasteur is the infectious disease division of the French Giant Sanofi, responsible for producing 1 Billion vaccine doses each year. Now they are looking to ‘evolve’ the vaccine R&D field, adapting their approach to find a broader spectrum defense against seasonal Influenza strains. However, the UK NIHR and PepTCell are also after the same […]

November 12, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 12 Nov 2015

Interview: CureVac, the ‘RNA’ People’s Pioneering Strategy to get mRNA Therapies onto the Market

I am still at the mRNA Convention in Berlin…and was invited for a second interview – this time with the ‘RNA People’, battling to be the first to get an mRNA Drug onto the Worldwide Market. I had a chat with Franz-Werner Haas, the Chief Corporate Office of CureVac. We talked a lot about this […]

November 12, 2015 - 1 minutemin - By Philip Hemme

News and Trends 12 Nov 2015

EU’s Largest Private Biotech talking on the Future of mRNA Therapies

Today is the 3rd International mRNA Health Conference in Berlin. I jumped in the metro to go there and interview the most successful people of the field… We first interviewed Sean Marett, COO of BioNTech. This German Biotech is the largest private Biotech in EU and so far counts over 400 employees…BioNTech also recently signed […]

November 12, 2015 - 1 minutemin - By Philip Hemme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

What will Happen now the Microbiome Hype has Broken into the Immuno-Oncology Field?

Epigenetics Drug Discovery has a New Champion!

Interview with the CEO of Genfit – The Billion Euro Liver Biotech on its phase III NASH Drug

Swissmedic Approves Zambon and Newron Therapy against Parkinson’s

What are Money-Magnet Moderna’s future plans? French Founding CEO explains here

What happened this week? mRNA Therapies, TCR & Algae Beer

We were at the Berlin Office Opening of the Leading German Bioinformatics Company

Curetis Molecular Diagnostics IPO Exceeds Expectations

Biotech of the Week: Lexogen and it’s Transcriptomic Approach to Disease

Sanofi’s COBRA Research to Tackle the Challenge of A Universal Influenza Vaccine for Winter

Interview: CureVac, the ‘RNA’ People’s Pioneering Strategy to get mRNA Therapies onto the Market

EU’s Largest Private Biotech talking on the Future of mRNA Therapies

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!